US Inhaled Insulin Dose Titration Study
Completed · Phase 3
Conditions studied: Diabetes Mellitus, Type 2
In brief
This study will examine how to dose Exubera (inhaled insulin) in patients who are not well controlled on two or more diabetes pills. This study should show that a large number of patients enrolled in the study can reach the target Hemoglobin A1C levels (7% or less) that have been set by the American Diabetes Association (ADA). Target goals should be achieved by adjusting the Exubera dose either weekly or twice weekly. Patients will also receive nutritional counseling and diabetes education as part of the study.
Key facts
- Study ID
- NCT00246623
- Run by
- Pfizer
- People needed
- 120
- Starts
- 2005-11-01
- Expected to finish
- 2007-03-01
- Last updated by the study team
- 2008-02-08
Who can join
Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Male and female, age >= 18 years and <= 80 years, with a diagnosis of type 2 diabetes made at least 6 months prior to study entry, with hemoglobin A1C 7.5-10%
- Currently treated with 2 or more oral antidiabetic agents (sulfonylureas, metformin, and/or thiazolidinediones)
You may not qualify if…
- Type 1 diabetes
- Smoking within the past 6 months or significant pulmonary diseases
Where it is running
- Pfizer Investigational Site — Birmingham, Alabama, United States
- Pfizer Investigational Site — Los Angeles, California, United States
- Pfizer Investigational Site — New Britain, Connecticut, United States
- Pfizer Investigational Site — Norwalk, Connecticut, United States
- Pfizer Investigational Site — Hollywood, Florida, United States
- Pfizer Investigational Site — Atlanta, Georgia, United States
- Pfizer Investigational Site — Boise, Idaho, United States
- Pfizer Investigational Site — Hayden, Idaho, United States
- Pfizer Investigational Site — Baton Rouge, Louisiana, United States
- Pfizer Investigational Site — Boston, Massachusetts, United States
- Pfizer Investigational Site — Albany, New York, United States
- Pfizer Investigational Site — Syracuse, New York, United States
- Pfizer Investigational Site — Dallas, Texas, United States
- Pfizer Investigational Site — El Paso, Texas, United States
- Pfizer Investigational Site — San Antonio, Texas, United States
- Pfizer Investigational Site — Bennington, Vermont, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.